Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany

Clinical and Experimental Rheumatology

Volumn 31, Issue 3, 2013, Pages 400-408

  Beresniak, A ^a,b   Baerwald, C ^c   Zeidler, H ^d   Kruger, K ^e   Neubauer, A S ^f   Dupont, D ^f   Merkesdal, S ^g  

^a DATA MINING INTERNATIONAL   (Switzerland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d Rheumatologikum Hannover   (Germany)

^e Praxiscentrum St Bonifatius   (Germany)

^f BRISTOL MYERS SQUIBB   (United States)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Abatacept; Anti TNF; Cost Effectiveness; Modelling; Rheumatoid arthritis; Rituximab

Indexed keywords

ABATACEPT; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; GERMANY; HEALTH CARE UTILIZATION; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SIMULATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; GERMANY; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878367258     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. ROSERY H, BERGEMANN R, MAXION-BERGEMANN S: International variation in resource utilisation and treatment costs for rheumatoid arthritis - a systematic literature review. Pharmacoeconomics 2005; 23: 243-57.
2. RUOF J, HÜLSEMANN J, MITTENDORF T et al.: Costs of rheumatoid arthritis in Germany: A micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003; 62: 544-9.
3. HÜLSEMANN J, MITTENDORF T, MERKESDAL S et al.: Direct costs related to rheumatoid arthritis: The patient perspective. Ann Rheum Dis 2005; 64: 1456-61.
4. HÜLSEMANN J, RUOF J, ZEIDLER H, MITTENDORF T: Costs in rheumatology: Results and lessons learned from the 'Hannover costing study'. Rheumatol Int 2006; 26: 704-11.
5. HUSCHER D, MERKESDAL S, THIELE K. et al.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 1175-83.
6. SCHNEIDER S, SCHMITT G, RICHTER W: Prevalence and correlates of inflammatory arthritis in Germany: Data from the first national health survey. Arthritis Intl 2006; 27: 29-38.
7. LACKI J: Management of the patient with severe refractory rheumatoid arthritis: Are the newer treatment options worth considering?. BioDrugs 2000; 13: 425-35.
8. O'DELL J: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591- 602.
9. BAZZICHI L, ROSSI P, GIACOMELLI C et al.: A proposal of simple calculation (eri calculator) to predict the early response to TNF- a blockers therapy in rheumatoid arthritis. Rheumatol Int 2012; 32: 349-56.
10. BOMBARDIERI S, RUIZ A, FARDELLONE P et al.: Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007; 46: 1191-9.
11. KEYSTONE E, FLEISCHMANN R, EMERY P et al.: Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 2007; 56: 3896-908.
12. GENOVESE M, SCHIFF M, LUGGEN M et al.: Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 547-54.
13. COHEN S, EMERY P, GREENWALD M et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
14. SCHÄDLICH P, ZEIDLER H, ZINK A et al.: Modelling cost effectiveness and cost utility of sequential dmard therapy including leflunomide in rheumatoid arthritis in Germany. Pharmacoeconomics 2005; 23: 377-93.
15. HALLINEN TA, SOINI EJ, EKLUND K, PUOLAKKA K: Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010; 49: 767-77.
16. MERKESDAL S, KIRCHHOFF T, WOLKA D, LADINEK G, KIELHORN A, RUBBERT-ROTH A: Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ 2010; 11: 95-104.
17. RUSSELL A, BERESNIAK A, BESSETTE L et al.: Cost-effectiveness modeling of abatacept versus other biologic agents in dmards and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009; 28: 403-12.
18. SARAUX A, GOSSEC L, GOUPILLE P et al.: Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology (Oxford) 2010; 49: 733-40.
19. CIMMINO MA, LEARDINI G, SALAFFI F et al.: Assessing the cost-effectiveness of biologic agents for the management of moderateto- severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: A modelling approach. Clin Exp Rheumatol 2011; 29: 633-41.
20. PUOLAKKA K, BLÅFIELD H, KAUPPI M et al.: Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open Rheumatol J 2012; 6: 38-43.
21. BERESNIAK A, ARIZA-ARIZA R, GARCIALLORENTE JF, RAMIREZ-ARELLANO A, DUPONT D: Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam. Epub Jun 28 2011.
22. GABRIEL S, DRUMMOND M, MAETZEL A et al.: Omeract 6 economics working group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003; 30: 887-90.
23. WEINSTEIN M: Recent developments in decision- analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24: 1043- 53.
24. KEYSTONE E, ARANDA R, BECKER J et al.: Efficacy of abatacept through 1 year of the attain trial in patients with ra, regardless of reason for failure of prior anti-TNF therapy or number of prior anti-TNF therapies used. Annals Rheum Dis 2008; 67: 196.
25. ZINK A, LISTING J, STRANGFELD A et al.: Dosisanpassung bei patienten mit rheumatoider arthritis unter therapie mit infliximab in der rheumatologischen versorgung in dejutschland. Z Rheumatol 2006; 65: 441-6.
26. MEASE P, COHEN S, GAYLIS N et al.: Efficacy, safety and dose frequency of retreatment with rituximab in RA: Results from a randomized controlled trial (Sunrise). Arthritis Rheum ACR 2008; 58: Abstract 1212: S619.
27. EDITORIAL: Nice and new drugs for rheumatoid arthritis. Lancet 2008; 371: 1477.
28. OSIRI M, KAMOLRATANAKUL P, MAETZEL A, TUGWELL P: Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. Rheumatol Int 2007; 27: 1063-9.
29. ETHGEN O, KONCZ T: Modelling the sustainability of the DAS28 reduction with abatacept versus rituximab for rheumatoid arthritis patients with an inadequate response to anti-TNF therapy. Ann Rheum Dis 2008; 67 (Suppl. II: 191.
30. DAVIES A, CIFALDI M, SEGURADO O, WEISMAN M: Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009; 36: 16-26.
31. BERESNIAK A, RUSSELL AS, HARAOUI B, BESSETTE L, BOMBARDIER C, DURU G: Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol 2007; 34: 2193-200.
32. NEUMANN PJ, MC W: Legislating against use of cost-effectiveness information. N Engl J Med 2010; 363: 1495-97.
33. SALAFFI F, CAROTTI M, CIAPETTI A, GASPARINI S, GRASSI W: A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 661-71.
34. BANSBACK N, ARA R, KARNON J, ANIS A: Economic evaluations in rheumatoid arthritis: A critical review of measures used to define health states. Pharmacoeconomics 2008; 26: 395-408.
35. MAETZEL A, TUGWELL P, BOERS M et al.: Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a reference case. J Rheumatol 2003; 30: 891-6.